Citations (73)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Bonnie W. Leung, Christopher J. Fay, Jordan T. Said, Anthony R. Sheets, Christine G. Lian, Jennifer R. Brown, Jorge J. Castillo, Shayna Sarosiek, Catherine Flynn & Nicole R. LeBoeuf. (2023) Localized upper extremity edema secondary to Bruton’s tyrosine kinase inhibition. Leukemia & Lymphoma 0:0, pages 1-4.
Read now
Read now
Ahmet Emre Eskazan. (2019) Imatinib mesylate in the management of chemotherapy-induced pulmonary toxicity: a double-edged sword. Acta Oncologica 58:1, pages 123-124.
Read now
Read now
Mayte Coiras, Juan Ambrosioni, Francisco Cervantes, José M. Miró & José Alcamí. (2017) Tyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infection. Expert Opinion on Drug Safety 16:5, pages 547-559.
Read now
Read now
Fabio Stagno, Stefania Stella, Antonio Spitaleri, Maria Stella Pennisi, Francesco Di Raimondo & Paolo Vigneri. (2016) Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes. Expert Review of Anticancer Therapy 16:3, pages 273-278.
Read now
Read now
Benedito A Carneiro, Jason B Kaplan & Francis J Giles. (2015) Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events. Expert Review of Hematology 8:4, pages 457-479.
Read now
Read now
Michele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, Francesca Palandri & Gianantonio Rosti. (2014) Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. Expert Review of Hematology 7:3, pages 397-406.
Read now
Read now
Jeffrey H Lipton & Dennis (Dong Hwan) Kim. (2013)
Omacetaxine mepesuccinate for management of chronic myeloid leukemia. Expert Opinion on Orphan Drugs 1:9, pages 745-754.
Read now
Read now
Articles from other publishers (66)
Marika Bini Antunes, Sara Pinto Cardeal, Manuel Magalhães, Emídio Vale-Fernandes, Márcia Barreiro, Rosália Sá & Mário Sousa. (2023) Preservation of fertility in female patients with hematologic diseases. Blood Reviews 62, pages 101115.
Crossref
Crossref
Benjamin C. S. Leow, Chung H. Kok, David T. Yeung, Timothy P. Hughes, Deborah L. White & Laura N. Eadie. (2023) The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanism. Scientific Reports 13:1.
Crossref
Crossref
Konstantin Golovine, Gleb Abalakov, Zhaorui Lian, Srinivas Chatla, Adam Karami, Kumaraswamy Naidu Chitrala, Jozef Madzo, Margaret Nieborowska-Skorska, Jian Huang & Tomasz Skorski. (2023) ABL1 kinase as a tumor suppressor in AML1-ETO and NUP98-PMX1 leukemias. Blood Cancer Journal 13:1.
Crossref
Crossref
Lando Janssen, Maria T. E. Hopman, Greetje J. A. Swaans, Neeltje A. E. Allard, Marti Boss, Daphne Lobeek, Martin Gotthardt, Tom J. J. Schirris, Nicole M. A. Blijlevens & Silvie Timmers. (2023) Impact of tyrosine kinase inhibitors on glucose control and insulin regulation in patients with chronic myeloid leukemia. American Journal of Physiology-Endocrinology and Metabolism 324:3, pages E209-E216.
Crossref
Crossref
Andreas Hochhaus, Delphine Réa, Carla Boquimpani, Yosuke Minami, Jorge E. Cortes, Timothy P. Hughes, Jane F. Apperley, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong-Wook Kim, Andre Abdo, Laura Maria Fogliatto, Philipp le Coutre, Koji Sasaki, Dennis Dong Hwan Kim, Susanne Saussele, Mario Annunziata, Naeem Chaudhri, Lynette Chee, Valentin García-Gutiérrez, Shruti Kapoor, Alex Allepuz, Sara Quenet, Véronique Bédoucha & Michael J. Mauro. (2023) Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia 37:3, pages 617-626.
Crossref
Crossref
Jeffrey H. Lipton, Tim H. Brümmendorf, Carlo Gambacorti-Passerini, Valentin Garcia-Gutiérrez, Michael W. Deininger & Jorge E. Cortes. (2022) Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. Blood Reviews 56, pages 100968.
Crossref
Crossref
Junichiro Yuda, Noriko Doki, Hiroshi Matsuoka, Takafumi Yokota, Akihiro Tomita, Naoto Takahashi, Itaru Matsumura, Kohmei Kubo, Tatsunori Goto, Keita Kirito, Akio Maki, Makoto Aoki, Alex Allepuz & Yosuke Minami. (2022) Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study. Cancer Medicine.
Crossref
Crossref
Masamitsu Takaba, Takayuki Iwaki, Tomohiro Arakawa, Takaaki Ono, Yuichiro Maekawa & Kazuo Umemura. (2022) Dasatinib suppresses atherosclerotic lesions by suppressing cholesterol uptake in a mouse model of hypercholesterolemia. Journal of Pharmacological Sciences 149:3, pages 158-165.
Crossref
Crossref
Kim Vettenranta, Veronika Dobsinska, Gabriella Kertész, Peter Svec, Jochen Buechner & Kirk R. Schultz. (2022) What Is the Role of HSCT in Philadelphia-Chromosome–Positive and Philadelphia-Chromosome–Like ALL in the Tyrosine Kinase Inhibitor Era?. Frontiers in Pediatrics 9.
Crossref
Crossref
R. Rodia, F. Pani, G. Caocci, G. La Nasa, M. P. Simula, O. Mulas, F. Velluzzi, A. Loviselli, S. Mariotti & F. Boi. (2021) Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia on tyrosine kinase inhibitors. Journal of Endocrinological Investigation 45:2, pages 291-300.
Crossref
Crossref
Cecilia C. Ayala-Aguilera, Teresa Valero, Álvaro Lorente-Macías, Daniel J. Baillache, Stephen Croke & Asier Unciti-Broceta. (2021) Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis. Journal of Medicinal Chemistry 65:2, pages 1047-1131.
Crossref
Crossref
Sang-A Kim, Byoung Soo Kwon, Jin-Haeng Chung, Ji Yun Lee, Soo-Mee Bang & Jeong-Ok Lee. (2022) Interstitial pneumonitis associated with dasatinib treatment for chronic myeloid leukemia or acute lymphoblastic leukemia: case series and a literature review. Therapeutic Advances in Respiratory Disease 16, pages 175346662211353.
Crossref
Crossref
Carolin Temps, Daniel Lietha, Emily R. Webb, Xue-Feng Li, John C. Dawson, Morwenna Muir, Kenneth G. Macleod, Teresa Valero, Alison F. Munro, Rafael Contreras-Montoya, Juan R. Luque-Ortega, Craig Fraser, Henry Beetham, Christina Schoenherr, Maria Lopalco, Mark J. Arends, Margaret C. Frame, Bin-Zhi Qian, Valerie G. Brunton, Neil O. Carragher & Asier Unciti-Broceta. (2021) A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability. Cancer Research 81:21, pages 5438-5450.
Crossref
Crossref
Meinolf Suttorp, Andrea Webster Carrion & Nobuko Hijiya. (2021) Chronic Myeloid Leukemia in Children: Immune Function and Vaccinations. Journal of Clinical Medicine 10:18, pages 4056.
Crossref
Crossref
Lauren R. Alesi, Amy L. Winship & Karla J. Hutt. (2021) Evaluating the impacts of emerging cancer therapies on ovarian function. Current Opinion in Endocrine and Metabolic Research 18, pages 15-28.
Crossref
Crossref
Lia N. Phillips & Nobuko Hijiya. (2021) Tyrosine Kinase Inhibitors and Beyond for Chronic Myeloid Leukemia in Children. Pediatric Drugs 23:3, pages 241-251.
Crossref
Crossref
Li Zhang, Li Meng, Bingcheng Liu, Yanli Zhang, Huanling Zhu, Jiuwei Cui, Aining Sun, Yu Hu, Jie Jin, Hao Jiang, Xi Zhang, Yan Li, Li Liu, Wanggang Zhang, Xiaoli Liu, Jian Gu, Jianhui Qiao, Guifang Ouyang, Xin Liu, Jianmin Luo, Ming Jiang, Xiaobao Xie, Jianyong Li, Chunting Zhao, Mei Zhang, Tonghua Yang & Jianxiang Wang. (2021) Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study. Clinical Cancer Research 27:1, pages 70-77.
Crossref
Crossref
Yanhong Liu, Lingchao Li, Jiyong Liu, Mengnan Yang, Honglan Wang, Xuxin Chu, Jianping Zhou, Meirong Huo & Tingjie Yin. (2021) Biomineralization-inspired dasatinib nanodrug with sequential infiltration for effective solid tumor treatment. Biomaterials 267, pages 120481.
Crossref
Crossref
Lorena Vigón, Sara Rodríguez-Mora, Alejandro Luna, Virginia Sandonís, Elena Mateos, Guiomar Bautista, Juan Luis Steegmann, Nuria Climent, Montserrat Plana, Pilar Pérez-Romero, Fernando de Ory, José Alcamí, Valentín García-Gutierrez, Vicente Planelles, María Rosa López-Huertas & Mayte Coiras. (2020) Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection. Biochemical Pharmacology 182, pages 114203.
Crossref
Crossref
Liyi Fu, Fengming Zou, Qingwang Liu, Beilei Wang, Junqing Wang, Huamin Liang, Xiaofei Liang, Jing Liu, Jinjun Shi & Qingsong Liu. (2020) An ultra-long circulating nanoparticle for reviving a highly selective BCR-ABL inhibitor in long-term effective and safe treatment of chronic myeloid leukemia. Nanomedicine: Nanotechnology, Biology and Medicine 29, pages 102283.
Crossref
Crossref
Yoshinobu Seki, Ouki Nagano, Ryo Koda, Shinichi Morita & Go Hasegawa. (2020) Pathological findings suggesting vascular endothelial damage in multiple organs in chronic myelogenous leukemia patients on long-term tyrosine kinase inhibitor therapy. International Journal of Hematology 112:4, pages 584-591.
Crossref
Crossref
Wael Salem, Jacqueline R. Ho, Irene Woo, Sue A. Ingles, Karine Chung, Richard J. Paulson & Lynda K. McGinnis. (2020) Long-term imatinib diminishes ovarian reserve and impacts embryo quality. Journal of Assisted Reproduction and Genetics 37:6, pages 1459-1466.
Crossref
Crossref
Masao Hagihara, Jian Hua, Morihiro Inoue, Tomoyuki Uchida, Shiro Ide, Shin Ohara & Tomoiku Takaku. (2020) Nilotinib treatment induced large granular lymphocyte expansion and maintenance of longitudinal remission in a Philadelphia chromosome-positive acute lymphoblastic leukemia. International Journal of Hematology 111:5, pages 719-723.
Crossref
Crossref
Satoshi KaitoYujiro Nakajima, Konan HaraTakashi Toya, Tetsuya NishidaNaoyuki UchidaJunichi MukaeTakahiro FukudaYukiyasu OzawaMasatsugu TanakaKazuhiro IkegameYuta Katayama, Takuro KuriyamaJunya Kanda, Yoshiko AtsutaMasao Ogata, Ayumi Taguchi & Kazuteru Ohashi. (2020) Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation. Blood Advances 4:6, pages 1051-1061.
Crossref
Crossref
Bogyeong Kang, Yeongeun Kim, Tae Jun Park & Hee Young Kang. (2020) Dasatinib, a second-generation tyrosine kinase inhibitor, induces melanogenesis via ERK-CREB-MITF-tyrosinase signaling in normal human melanocytes. Biochemical and Biophysical Research Communications 523:4, pages 1034-1039.
Crossref
Crossref
Dakota Gustafson, Jason E. Fish, Jeffrey H. Lipton & Nazanin Aghel. (2020) Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia. Current Hematologic Malignancy Reports 15:1, pages 20-30.
Crossref
Crossref
Richard E. Clark. (2019) Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice. Current Hematologic Malignancy Reports 14:6, pages 507-514.
Crossref
Crossref
Beatriz Colom-Fernández, Anna Kreutzman, Ana Marcos-Jiménez, Valentín García-Gutiérrez, Carlos Cuesta-Mateos, Itxaso Portero-Sainz, Yaiza Pérez-García, Luis Felipe Casado, Fermín Sánchez-Guijo, Joaquín Martínez-López, Rosa M. Ayala, Concha Boqué, Blanca Xicoy, Isabel Montero, César Soto, Raquel Paz, Gabriela Silva, Lorena Vega-Piris, Juan Luis Steegmann & Cecilia Muñoz-Calleja. (2019) Immediate Effects of Dasatinib on the Migration and Redistribution of Naïve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients. Frontiers in Pharmacology 10.
Crossref
Crossref
Jessica Wu, Yanjun Chen, Lindsey Hageman, Liton Francisco, Emily C. Ness, Mariel Parman, Michelle Kung, James A. Watson, Daniel J. Weisdorf, David S. Snyder, Philip B. McGlave, Stephen J. Forman, Mukta Arora, Saro H. Armenian, Ravi Bhatia & Smita Bhatia. (2019) Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report. Cancer 125:22, pages 4033-4042.
Crossref
Crossref
Xuelin Dou, Yazhen Qin, Xiaojun Huang & Qian Jiang. (2019) Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy. The Oncologist 24:11, pages e1141-e1147.
Crossref
Crossref
Núria Climent & Montserrat Plana. (2019) Immunomodulatory Activity of Tyrosine Kinase Inhibitors to Elicit Cytotoxicity Against Cancer and Viral Infection. Frontiers in Pharmacology 10.
Crossref
Crossref
Kathryn E. Flynn, Judith M. Myers, Anita D'Souza, Charles A. Schiffer, James E. Thompson & Ehab Atallah. (2019) Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. The Oncologist 24:9, pages 1253-1258.
Crossref
Crossref
Gemma M. Austin, Katy Knight, Joanne Bell, Anthony Carter, Earnest Heartin, David Watson, Letizia Foroni, Stephen E. Christmas, Fotios Polydoros & Richard E. Clark. (2018) The effect on lymphocyte subsets of decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trial. British Journal of Haematology 185:4, pages 791-793.
Crossref
Crossref
Takeshi Sasaki, Omar E. Franco, Kohshi Ohishi, Yana Filipovich, Kenichiro Ishii, Susan E. Crawford, Naoto Takahashi, Naoyuki Katayama, Yoshiki Sugimura & Simon W. Hayward. (2018) Tyrosine kinase inhibitor therapy prescribed for non‐urologic diseases can modify PSA titers in urology patients. The Prostate 79:3, pages 259-264.
Crossref
Crossref
Miriam S. Hohmann, David M. Habiel, Ana L. Coelho, Waldiceu A. VerriJr.Jr. & Cory M. Hogaboam. (2019)
Quercetin Enhances Ligand-induced Apoptosis in Senescent Idiopathic Pulmonary Fibrosis Fibroblasts and Reduces Lung Fibrosis
In Vivo
. American Journal of Respiratory Cell and Molecular Biology 60:1, pages 28-40.
Crossref
Crossref
Ehab Atallah, Charles A. Schiffer, Kevin P. Weinfurt, Mei-Jie Zhang, Jerald P. Radich, Vivian G. Oehler, Javier Pinilla-Ibarz, Michael W. N. Deininger, Li Lin, Richard A. Larson, Michael J. Mauro, Joseph O. Moore, Ellen K. Ritchie, Neil P. Shah, Richard T. Silver, Martha Wadleigh, Jorge Cortes, James Thompson, Jessica Guhl, Mary M. Horowitz & Kathryn E. Flynn. (2018) Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. BMC Cancer 18:1.
Crossref
Crossref
Mercedes Bermejo, Juan Ambrosioni, Guiomar Bautista, Núria Climent, Elena Mateos, Cristina Rovira, Sara Rodríguez-Mora, María Rosa López-Huertas, Valentín García-Gutiérrez, Juan Luis Steegmann, Rafael Duarte, Francisco Cervantes, Montserrat Plana, José M. Miró, José Alcamí & Mayte Coiras. (2018) Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors. Biochemical Pharmacology 156, pages 248-264.
Crossref
Crossref
Chikara HIRASE & Itaru MATSUMURA. (2018) Thromboembolism in TKI therapyチロシンキナーゼ阻害薬（TKI）治療と血栓塞栓症. Japanese Journal of Thrombosis and Hemostasis 29:5, pages 473-486.
Crossref
Crossref
Susanne Isfort, Martina Crysandt, Deniz Gezer, Steffen Koschmieder, Tim H. Brümmendorf & Dominik Wolf. 2018. Small Molecules in Hematology. Small Molecules in Hematology
87
108
.
Anna Kreutzman, Beatriz Colom-Fernández, Ana Marcos Jiménez, Mette Ilander, Carlos Cuesta-Mateos, Yaiza Pérez-García, Cristina Delgado Arévalo, Oscar Brück, Henna Hakanen, Jani Saarela, Alvaro Ortega-Carrión, Ana de Rosendo, Alba Juanes-García, Juan Luis Steegmann, Satu Mustjoki, Miguel Vicente-Manzanares & Cecilia Muñoz-Calleja. (2017) Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner. Clinical Cancer Research 23:21, pages 6697-6707.
Crossref
Crossref
Nesrine S. El-Mezayen, Wessam F. El-Hadidy, Wessam M. El-Refaie, Th.I. Shalaby, Mahmoud M. Khattab & Aiman S. El-Khatib. (2017) Hepatic stellate cell-targeted imatinib nanomedicine versus conventional imatinib: A novel strategy with potent efficacy in experimental liver fibrosis. Journal of Controlled Release 266, pages 226-237.
Crossref
Crossref
Jorge E. Cortes, Carlo Gambacorti-Passerini, Dong-Wook Kim, Hagop M. Kantarjian, Jeff H. Lipton, Amit Lahoti, Moshe Talpaz, Ewa Matczak, Elly Barry, Eric Leip, Tim H. Brümmendorf & H. Jean Khoury. (2017) Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias. Clinical Lymphoma Myeloma and Leukemia 17:10, pages 684-695.e6.
Crossref
Crossref
Satoshi Nishiwaki, Matsuyoshi Maeda, Masahiro Yamada, Shingo OkunoYasuhiko HaradaKotaro SuzukiShingo KurahashiFumihiro Urano, Shozo Okamura & Isamu Sugiura. (2017) Clinical efficacy of fecal occult blood test and colonoscopy for dasatinib-induced hemorrhagic colitis in CML patients. Blood 129:1, pages 126-128.
Crossref
Crossref
L Charaf, F-X Mahon, I Lamrissi-Garcia, I Moranvillier, F Beliveau, B Cardinaud, S Dabernat, H de Verneuil, F Moreau-Gaudry & A Bedel. (2016) Effect of tyrosine kinase inhibitors on stemness in normal and chronic myeloid leukemia cells. Leukemia 31:1, pages 65-74.
Crossref
Crossref
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors
641
693
.
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors
221
242
.
Radana Karlíková, Jitka Široká, David Friedecký, Edgar Faber, Marcela Hrdá, Kateřina Mičová, Iveta Fikarová, Alžběta Gardlo, Hana Janečková, Ivo Vrobel & Tomáš Adam. (2016) Metabolite Profiling of the Plasma and Leukocytes of Chronic Myeloid Leukemia Patients. Journal of Proteome Research 15:9, pages 3158-3166.
Crossref
Crossref
J L Steegmann, M Baccarani, M Breccia, L F Casado, V García-Gutiérrez, A Hochhaus, D-W Kim, T D Kim, H J Khoury, P Le Coutre, J Mayer, D Milojkovic, K Porkka, D Rea, G Rosti, S Saussele, R Hehlmann & R E Clark. (2016) European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 30:8, pages 1648-1671.
Crossref
Crossref
Craig Fraser, John C. Dawson, Reece Dowling, Douglas R. Houston, Jason T. Weiss, Alison F. Munro, Morwenna Muir, Lea Harrington, Scott P. Webster, Margaret C. Frame, Valerie G. Brunton, E. Elizabeth Patton, Neil O. Carragher & Asier Unciti-Broceta. (2016) Rapid Discovery and Structure–Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase. Journal of Medicinal Chemistry 59:10, pages 4697-4710.
Crossref
Crossref
Mohamed Shanshal, Andrew Shakespeare, Seshadri Thirumala, Boyd Fenton & Donald P. Quick. (2016) Dasatinib-Induced T-Cell-Mediated Colitis: A Case Report and Review of the Literature. Acta Haematologica 136:4, pages 219-228.
Crossref
Crossref
A.A. Stepanenko & V.V. Dmitrenko. (2015) Pitfalls of the MTT assay: Direct and off-target effects of inhibitors can result in over/underestimation of cell viability. Gene 574:2, pages 193-203.
Crossref
Crossref
Michael G. Ozawa, Mark D. Ewalt & Dita Gratzinger. (2015) Dasatinib-related Follicular Hyperplasia. American Journal of Surgical Pathology 39:10, pages 1363-1369.
Crossref
Crossref
D Russo, M Malagola, C Skert, V Cancelli, D Turri, P Pregno, M Bergamaschi, M Fogli, N Testoni, A De Vivo, F Castagnetti, E Pungolino, F Stagno, M Breccia, B Martino, T Intermesoli, G R Cambrin, G Nicolini, E Abruzzese, M Tiribelli, C Bigazzi, E Usala, S Russo, A Russo-Rossi, M Lunghi, M Bocchia, A D'Emilio, V Santini, M Girasoli, R Di Lorenzo, S Bernardi, A Di Palma, B M Cesana, S Soverini, G Martinelli, G Rosti & M Baccarani. (2015) Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment. Blood Cancer Journal 5:9, pages e347-e347.
Crossref
Crossref
Karla Schmitt, Susanne Isfort, Steffen Koschmieder & Tim H. Brümmendorf. (2015) Myeloproliferative Neoplasien. best practice onkologie 10:5, pages 46-57.
Crossref
Crossref
Lisa Christiansson, Stina Söderlund, Sara Mangsbo, Henrik Hjorth-Hansen, Martin Höglund, Berit Markevärn, Johan Richter, Leif Stenke, Satu Mustjoki, Angelica Loskog & Ulla Olsson-Strömberg. (2015) The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses. Molecular Cancer Therapeutics 14:5, pages 1181-1191.
Crossref
Crossref
Valent?n Garc?a-Guti?rrez, Alejandra Martinez-Trillos, Jose Luis Lopez Lorenzo, Guiomar Bautista, Maria Luisa Martin Mateos, Alberto Alvarez-Larr?n, Ana Iglesias P?rez, Andr?s Romo Collado, Angeles Fernandez, Angeles Portero, Beatriz Cuevas, Concepci?n Ruiz, Esperanza Romero, Fernando Ortega, Isabel Mata, Jos? Tall?n, Maria del Carmen Garc?a Garay, Mar?a Jos? Ramirez S?nchez, Natalia de las Heras, Pilar Giraldo, Sabela Bobillo, Jos? Mar?a Guinea, Guillermo Deben, Sandra Valencia, Ana Sebrango, Concepci?n Boqu?, Bego?a Maestro & Juan Luis Steegmann. (2015) Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program. American Journal of Hematology 90:5, pages 429-433.
Crossref
Crossref
Jane F Apperley. (2015) Chronic myeloid leukaemia. The Lancet 385:9976, pages 1447-1459.
Crossref
Crossref
Jo?lle Guilhot, Claude Preudhomme, Francois Xavier Mahon & Fran?ois Guilhot. (2015) Analyzing molecular response in chronic myeloid leukemia clinical trials: Pitfalls and golden rules. Cancer 121:4, pages 490-497.
Crossref
Crossref
Andrew J. Innes & Jane F. Apperley. (2014) Chronic Myeloid Leukemia?Transplantation in the Tyrosine Kinase Era. Hematology/Oncology Clinics of North America 28:6, pages 1037-1053.
Crossref
Crossref
Marta Ceko, Nevena Milenkovic, Philipp le Coutre, Jörg Westermann & Gary R. Lewin. (2014) Inhibition of c-Kit signaling is associated with reduced heat and cold pain sensitivity in humans. Pain 155:7, pages 1222-1228.
Crossref
Crossref
Leonid Dubrovsky, Dmitry PankovElliott Joseph Brea, Tao DaoAndrew ScottSu Yan, Richard J O’ReillyCheng Liu & David A. Scheinberg. (2014) A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias. Blood 123:21, pages 3296-3304.
Crossref
Crossref
Senthilkumar S. Karuppagounder, Saurav Brahmachari, Yunjong Lee, Valina L. Dawson, Ted M. Dawson & Han Seok Ko. (2014) The c-Abl inhibitor, Nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease. Scientific Reports 4:1.
Crossref
Crossref
Michele BaccaraniSimona SoveriniCaterina De Benedittis. (2014) Molecular Monitoring and Mutations in Chronic Myeloid Leukemia: How to Get the Most out of Your Tyrosine Kinase Inhibitor. American Society of Clinical Oncology Educational Book:34, pages 167-175.
Crossref
Crossref
Matthias Wölfl, Stefanie SchwinnYoung-Eun Yoo, Marie L. ReßMatthias BraunMartin Chopra, Susanne C. SchreiberVictor I. Ayala, Claes Ohlen, Matthias Eyrich, Andreas Beilhack & Paul G. Schlegel. (2013) Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor–induced interleukin 12 synthesis. Blood 122:7, pages 1203-1213.
Crossref
Crossref
Michele BaccaraniMichael W. DeiningerGianantonio RostiAndreas HochhausSimona SoveriniJane F. ApperleyFrancisco CervantesRichard E. ClarkJorge E. CortesFrançois GuilhotHenrik Hjorth-HansenTimothy P. HughesHagop M. KantarjianDong-Wook KimRichard A. LarsonJeffrey H. LiptonFrançois-Xavier MahonGiovanni MartinelliJiri MayerMartin C. MüllerDietger NiederwieserFabrizio PaneJerald P. RadichPhilippe RousselotGiuseppe SaglioSusanne SaußeleCharles SchifferRichard SilverBengt SimonssonJuan-Luis Steegmann, John M. Goldman & Rüdiger Hehlmann. (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:6, pages 872-884.
Crossref
Crossref
P. Rousselot. (2012) Inhibiteur de tyrosine-kinase de seconde g?n?ration: place en 2012 en premi?re ligneSecond-generation tyrosine-kinase inhibitors: their role as a first-line treatment in 2012. Oncologie 14:10-11, pages 596-600.
Crossref
Crossref